The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In other good news, in September, the Food and Drug Administration (FDA) approved Lilly's new eczema treatment, Ebglyss. In the long-term ADjoin study, treatment with the monthly injection controlled ...

New results show Eli Lilly’s (LLY) Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the ...